triphenyltetrazolium has been researched along with charybdotoxin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, Y; Chen, L; Li, L; Qi, J; Qi, Z; Sun, K; Yang, R; Zhang, Z; Zhou, L | 1 |
1 other study(ies) available for triphenyltetrazolium and charybdotoxin
| Article | Year |
|---|---|
Cerebroside-A provides potent neuroprotection after cerebral ischaemia through reducing glutamate release and Ca²⁺ influx of NMDA receptors.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Analysis of Variance; Animals; Brain Ischemia; Calcium; Cerebral Infarction; Cerebrosides; Charybdotoxin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Glucose; Glutamic Acid; Hippocampus; Hypoxia; In Vitro Techniques; Infarction, Middle Cerebral Artery; Long-Term Potentiation; Male; Mice; Mice, Inbred C57BL; N-Methylaspartate; Neuroprotective Agents; Neurotoxins; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Tetrazolium Salts; Valine | 2012 |